In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Roivant Sciences Ltd. (NASDAQ:ROIV), a pharmaceutical company with a market capitalization of $7.8 billion and a "GOOD" financial health rating according to InvestingPro, disclosed on Thursday ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

Vivek Ramaswamy’s Roivant group has forged its biggest and most wide-ranging alliance to date, licensing dozens of drugs to Japan’s Sumitomo Dainippon Pharma in deal that includes a massive $3 ...

Viking Global's 13F stock portfolio increased from $27.44B to $30.90B, with holdings rising from 83 to 86. Read more to see ...

In Roivant, Pfizer has a partner with "a proven track record in late-stage inflammation and immunology drug development," said the big pharma's chief scientific officer Mikael Dolsten. Hiving off ...

He went on to graduate from Harvard and Yale Law School. Ramaswamy founded the pharmaceutical research company Roivant Sciences in 2014. He co-founded the Dublin asset management company Strive ...

Immunovant and Roivant Sciences said Wednesday their rare ... We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...

Roivant Sciences Ltd. (NASDAQ:ROIV), a pharmaceutical company with a market capitalization of $7.8 billion and a "GOOD" financial health rating according to InvestingPro, disclosed on Thursday that it ...